DRUG · Unmapped registry intervention
Surufatinib
Find medicine records ·
Find other trials using this name
Clinical trial
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
NCT05509699
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Anti-PD-1/L1
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedSurufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Extensive-Stage Small Cell Lung Cancerunresolved
Interventions
SurufatinibDRUG
Anti-PD-1/L1DRUG
Sponsors & collaborators
Hutchison Medipharma Limitedlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05509699 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.